Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norepinephrine vs Midodrine & Octreotide in HRS-AKI
NCT03455322Phase 4Completed
- Sponsor
- National Hepatology and Tropical Medicine Research Institute
- Start
- Aug 2018
- Primary completion
- Apr 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of norepinephrine, midodrine, Octreotide long-acting injection in hepatorenal syndrome type 1 (HRS-1), sponsored by National Hepatology and Tropical Medicine Research Institute. Started Aug 2018; status: completed.
02
Drugs
norepinephrinemidodrineOctreotide long-acting injection
03
Conditions
hepatorenal syndrome type 1 (HRS-1)
Beyond the preview
Go deeper on NCT03455322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03455322.